Business Context and Reporting Period
This Form 8-K Current Report was filed by American Healthcare REIT, Inc. on July 14, 2022. The filing discloses significant changes in executive leadership, specifically the transition of the Chief Operating Officer (COO) role and the appointment of a successor.
Key Financial Metrics
The filing does not report operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and employment terms.
Material Changes
Departure of Mathieu B. Streiff
- Role Transition: Mr. Streiff transitioned from Chief Operating Officer to Executive Vice President effective August 1, 2022, with a planned retirement from that position on January 1, 2023.
- Reason: The transition was not the result of any disagreement with the company.
- Board Status: Mr. Streiff intends to remain on the Board of Directors, subject to stockholder election at the 2023 annual meeting.
- Compensation Changes:
- Prorated annualized cash salary of $85,000 for the period August 1, 2022, through December 31, 2022.
- Beginning January 1, 2023, he will receive independent director compensation and expense reimbursements, waiving the equity retainer until the 2023 annual meeting.
- Forfeiture of performance-based vesting restricted stock units (RSUs) granted in October 2021 and any 2022 annual bonus.
- Retention of time-based vesting restricted shares of Class T common stock, subject to existing vesting schedules and accelerated vesting provisions upon change in control, death, or disability.
- COBRA medical coverage reimbursement for up to 18 months starting January 1, 2023.
Appointment of Gabriel M. Willhite
- New Role: Appointed Chief Operating Officer effective August 1, 2022. He will no longer serve as Executive Vice President, General Counsel.
- Compensation Package:
- Base Salary: $425,000 annually.
- Annual Bonus: Target of 100% of base salary ($425,000), with a maximum of 150%. Performance is split 70% on corporate goals (MFFO per share growth, net-debt-to-EBITDA ratio, same-property NOI growth) and 30% on individual goals.
- Equity Grants:
- Initial grants in 2023 with an aggregate grant-date value of not less than $850,000.
- 75% time-based restricted stock vesting in three equal annual installments.
- 25% performance-based RSUs cliff-vesting in Q1 2026 based on relative MFFO-per-share ranking versus a peer group (50% vest at threshold, 100% at target, 200% at maximum).
- Future annual equity grants of not less than $850,000 beginning in 2024, subject to board approval.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on operational performance. The primary risk disclosed relates to the transition of senior management and the associated compensation obligations. The company noted that Mr. Willhite's employment is at-will.
Investor Verification Checklist
- Verify the exact vesting schedules and performance metrics for Mr. Willhite's $850,000+ annual equity grants.
- Confirm the total cash and equity compensation costs associated with Mr. Streiff's transition and retirement package.
- Review the full text of the Transition Services Agreement (Exhibit 10.1) and the Willhite Offer Letter (Exhibit 10.2) for detailed terms.
- Monitor the 2023 annual meeting of stockholders for the election of Mr. Streiff to the Board of Directors.